Wu Yingchun, Wang Junmei, Sun Rui, Feng Guanqing, Li Wenzhao, Gui Yuejiang, Zheng Yanan
Department of Neurology, ORDOS Central Hospital, Ordos, China.
Front Neurol. 2022 Feb 14;13:798542. doi: 10.3389/fneur.2022.798542. eCollection 2022.
There is no clear consensus on the optimal endovascular treatment strategy for patients with ischemic stroke caused by ICAS-related large vessel occlusion (LVO). SPACEMAN, a novel thrombectomy technique that entails passing an aspiration catheter over the stent retriever and then retaining the microwire for angioplasty, has not been described. The aim of this prospective study was to evaluate our initial application of SPACEMAN and compare this technique with the Solumbra technique.
Forty-four consecutive patients with acute ischemic stroke resulting from ICAS-related LVO were randomly divided into two groups: Solumbra group ( = 22) and SPACEMAN group ( = 22). Demographic and clinical data were prospectively collected. Modified Rankin Scale (mRS) score of ≤ 2 of anterior circulation and mRS score ≤ 3 of posterior circulation at 3 months post-discharge was regarded as good prognosis.
The SPACEMAN group showed reduced mean time from femoral access to recanalization compared with the Solumbra group (39.55 ± 10.63 min vs. 50.73 ± 9.89 min, = 0.001). The overall recanalization rate in the entire cohort was 93.18% (41/44). At 3-month follow-up, the overall good prognosis rate was 47.73%; 13 patients (59.09%) in the SPACEMAN group and 8 (36.36%) in the Solumbra group showed good prognosis. One patient in the SPACEMAN group (4.55%) and two patients in the Solumbra group (9.09%) developed symptomatic intracranial hemorrhage. The overall mortality rate was 4.55% (2/44).
This study suggests that SPACEMAN exhibits a shorter operation revascularization time than the standard thrombectomy. Complications and prognosis were comparable between the two groups. The safety and efficacy of this novel technique need to be studied in larger patient series.
对于因颅内动脉粥样硬化性狭窄(ICAS)相关的大血管闭塞(LVO)导致的缺血性卒中患者,最佳血管内治疗策略尚无明确共识。SPACEMAN是一种新型取栓技术,该技术需要将抽吸导管穿过支架取栓器,然后保留微导丝进行血管成形术,但尚未见相关描述。本前瞻性研究的目的是评估我们对SPACEMAN的初步应用,并将该技术与Solumbra技术进行比较。
44例因ICAS相关的LVO导致急性缺血性卒中的连续患者被随机分为两组:Solumbra组(n = 22)和SPACEMAN组(n = 22)。前瞻性收集人口统计学和临床数据。出院后3个月时,前循环改良Rankin量表(mRS)评分≤2分且后循环mRS评分≤3分被视为预后良好。
与Solumbra组相比,SPACEMAN组从股动脉穿刺到血管再通的平均时间缩短(39.55±10.63分钟对50.73±9.89分钟,P = 0.001)。整个队列的总体再通率为93.18%(41/44)。在3个月的随访中,总体良好预后率为47.73%;SPACEMAN组13例患者(59.09%)和Solumbra组8例患者(36.36%)预后良好。SPACEMAN组1例患者(4.55%)和Solumbra组2例患者(9.09%)发生症状性颅内出血。总体死亡率为4.55%(2/44)。
本研究表明,与标准取栓术相比,SPACEMAN的手术再血管化时间更短。两组之间的并发症和预后相当。这种新技术的安全性和有效性需要在更大规模的患者系列中进行研究。